Janssen's Darunavir-Based Single-Tablet Effective In Late-Stage Switching Study
Switching to a once-daily single tablet containing four constituents that is centered on Janssen's protease inhibitor darunavir was non-inferior to other combination therapies after 48 weeks of therapy, say researchers running the Phase III EMERALD study.
You may also be interested in...
The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.
More Phase III data for Janssen's first once-daily single tablet containing four drugs for use against HIV Symtuza support its use in treatment-naïve patients; the product awaits US approval.
J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise. In February, Merck lowered sales expectations for its investigational "nuc" MK-3682.